Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun A Fleming, Chun Yew Fong, Uma Borate, Meagan A Jacoby, Daniel Nowak, Maria R Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood blood.2024025464.

https://doi.org/10.1182/blood.2024025464

Published: 2024

Includes: Supplemental data

Journal Articles

Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Blood (2024) 144 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2024-204760

Published: 2024

Journal Articles

The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient's NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Nanni Schmitt, Jana-Julia Siegler, Alexandra Beck, Lea Hoppe, Mohammed Abba, Alexander Streuer, Stefan Klein, Wolf-Karsten Hofmann, Christian Merz, Jens Pahl, Daniel Nowak

Blood (2024) 144 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2024-210275

Published: 2024

Journal Articles

Impact of Molecular Aberrations on Discordance Among Modalities of Blast Enumeration for Risk Stratification in Myelodysplastic Neoplasms

Laurenz Steiner, Navkirandeep Kaur, Johann-Christoph Jann, Alice Fabarius, Georgia Metzgeroth, Manja Meggendorfer, Wolf-Karsten Hofmann, Mohamad Jawhar, Daniel Nowak, Alexander Streuer

Blood (2024) 144 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2024-211446

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Rachel Cook, Meagan Jacoby, Daniel Nowak, Brenda Chyla, Ying Zhou, Grace Ku, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 319.

https://doi.org/10.1182/blood-2023-189446

Published: 2023

Journal Articles

Distinct and Targetable Role of Calcium and Calcium Sensing Receptor in Leukaemia

Blood (2023) 142 (Supplement 1): 5709.

https://doi.org/10.1182/blood-2023-177990

Published: 2023

Journal Articles

Instructive Interaction between Myelodysplastic Hematopoiesis and the Bone Marrow Microenvironment at Single Cell Level

Blood (2023) 142 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2023-186130

Published: 2023

Journal Articles

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Nanni Schmitt, Jana-Julia Siegler, Lena Wagner, Nicole Schulze, Alexandra Beck, Wolf-Karsten Hofmann, Torsten Haneke, Uwe Reusch, José Medina-Echeverz, Jan Endell, Thorsten Ross, Christian Merz, Daniel Nowak

Blood (2022) 140 (Supplement 1): 8815–8816.

https://doi.org/10.1182/blood-2022-169729

Published: 2022

Journal Articles

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 9749–9750.

https://doi.org/10.1182/blood-2022-165298

Published: 2022

Journal Articles

Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival

Laurenz Steiner, Navkirandeep Kaur, Alexander Streuer, Johann-Christoph Jann, Alice Fabarius, Georgia Metzgeroth, Wolf-Karsten Hofmann, Daniel Nowak, Mohamad Jawhar

Blood (2022) 140 (Supplement 1): 9831–9832.

https://doi.org/10.1182/blood-2022-168850

Published: 2022

Journal Articles

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 3054–3055.

https://doi.org/10.1182/blood-2022-159507

Published: 2022

Journal Articles

Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

Nanni Schmitt, Alexander Streuer, Justine Danner, Eva Altrock, Vladimir Riabov, Qingyu Xu, Felicitas Rapp, Nadine Weimer, Iris Palme, Verena Nowak, Julia Obländer, Melda Göl, Ali Darwich, Laurenz Steiner, Tobias Boch, Mohamad Jawhar, Georgia Metzgeroth, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2022) 140 (Supplement 1): 4009–4010.

https://doi.org/10.1182/blood-2022-168709

Published: 2022

Journal Articles

Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Johann-Christoph Jann, Alina Wein, Eva Altrock, Arwin Mehralivand, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Mohamad Jawhar, Christel Weiss, Georgia Metzgeroth, Jason M Foulks, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 4649.

https://doi.org/10.1182/blood-2021-150778

Published: 2021

Journal Articles

AFM28, a Novel Bispecific Innate Cell Engager (ICE ® ), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jana-Julia Götz, Jens Pahl, Nanni Schmitt, Thomas Müller, Torsten Haneke, Izabela Kozlowska, Séverine Sarlang, Stefan Knackmuss, Eike Peters, Uwe Reusch, Thorsten Ross, Daniel Nowak, Wolf-Karsten Hofmann, Christian Merz

Blood (2021) 138 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2021-152463

Published: 2021

Journal Articles

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Obländer, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak

Blood (2021) 138 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2021-150244

Published: 2021

Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Blood (2021) 138 (Supplement 1): 241.

https://doi.org/10.1182/blood-2021-145613

Published: 2021

Journal Articles

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Vanessa Kohl, MSc, Susanne Brendel, MTA, Johanna Flach, PhD, Helga Kleiner, MTA, Christel Weiss, PhD, Wolfgang Seifarth, PhD, Daniel Nowak, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD, Henning D. Popp

Blood (2019) 134 (Supplement_1): 5056.

https://doi.org/10.1182/blood-2019-122672

Published: 2019

Journal Articles

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

Blood (2019) 134 (Supplement_1): 4227.

https://doi.org/10.1182/blood-2019-128075

Published: 2019

Journal Articles

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Johann-Christoph Jann, Johanna Flach, PhD, Antje Knaflic, Eva Altrock, PhD, Nanni Schmitt, MSc, Alexander Streuer, Justine Danner, Franziska Hofmann, Verena Nowak, Nina Draeger, Julia Obländer, Iris Palme, Patrick Wuchter, MD, Ahmed Jawhar, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD PhD, Daniel Nowak, MD

Blood (2019) 134 (Supplement_1): 4218.

https://doi.org/10.1182/blood-2019-126431

Published: 2019

Journal Articles

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Nanni Schmitt, MSc, Eva Altrock, PhD, Johann-Christoph Jann, MD, Johanna Flach, PhD, Carla Sens-Albert, PhD, Justine Danner, Stefanie Uhlig, Jovita Pressler, Iris Palme, Verena Nowak, Julia Obländer, Lena Drangmeister, MD, Franziska La Meir, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, Daniel Nowak, MD

Blood (2018) 132 (Supplement 1): 942.

https://doi.org/10.1182/blood-2018-99-116341

Published: 2018

NARROW

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient's NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Impact of Molecular Aberrations on Discordance Among Modalities of Blast Enumeration for Risk Stratification in Myelodysplastic Neoplasms

Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

Distinct and Targetable Role of Calcium and Calcium Sensing Receptor in Leukaemia

Instructive Interaction between Myelodysplastic Hematopoiesis and the Bone Marrow Microenvironment at Single Cell Level

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models

Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

AFM28, a Novel Bispecific Innate Cell Engager (ICE ® ), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only